These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 35670341)
1. Divulging Incipient SARS-CoV-2 Delta (B.1.617.2) Variant: Possible Interference with Global Scenario. Ray SK; Mukherjee S Infect Disord Drug Targets; 2023; 23(1):e060622205636. PubMed ID: 35670341 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination. Yang W; Shaman J medRxiv; 2021 Nov; ():. PubMed ID: 34845460 [TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466 [TBL] [Abstract][Full Text] [Related]
4. Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Trobajo-Sanmartín C; Martínez-Baz I; Miqueleiz A; Fernández-Huerta M; Burgui C; Casado I; Baigorría F; Navascués A; Castilla J; Ezpeleta C Microbiol Spectr; 2022 Apr; 10(2):e0000822. PubMed ID: 35412379 [TBL] [Abstract][Full Text] [Related]
6. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815 [TBL] [Abstract][Full Text] [Related]
7. Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals. Caserta LC; Martins M; Cronk B; Anderson R; Eldridge H; Gallow D; Kruppa F; Plocharczyk E; Diel DG Microbiol Spectr; 2022 Oct; 10(5):e0056322. PubMed ID: 36165775 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
9. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
10. Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021. Malden DE; Bruxvoort KJ; Tseng HF; Ackerson B; Choi SK; Florea A; Tubert J; Takhar H; Aragones M; Hong V; Talarico CA; McLaughlin JM; Qian L; Tartof SY MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(40):1415-1419. PubMed ID: 34618801 [TBL] [Abstract][Full Text] [Related]
11. Rapid Control of a SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Community Outbreak: The Successful Experience in Pingtung County of Taiwan. Shy CG; Lu JH; Lin HC; Hung MN; Chang HC; Lu ML; Chao HR; Chen YS; Wang PS Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162443 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224 [TBL] [Abstract][Full Text] [Related]
13. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225 [TBL] [Abstract][Full Text] [Related]
14. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022. Wolf JM; Wolf LM; Bello GL; Maccari JG; Nasi LA J Med Virol; 2023 Jan; 95(1):e28366. PubMed ID: 36458547 [TBL] [Abstract][Full Text] [Related]
15. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. Ma C; Chen X; Mei F; Xiong Q; Liu Q; Dong L; Liu C; Zou W; Zhan F; Hu B; Liu Y; Liu F; Zhou L; Xu J; Jiang Y; Xu K; Cai K; Chen Y; Yan H; Lan K Emerg Microbes Infect; 2022 Dec; 11(1):567-572. PubMed ID: 35060426 [TBL] [Abstract][Full Text] [Related]
16. RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity. Yaniv K; Ozer E; Lewis Y; Kushmaro A Water Res; 2021 Dec; 207():117808. PubMed ID: 34753092 [TBL] [Abstract][Full Text] [Related]
17. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021. Taylor CA; Patel K; Pham H; Whitaker M; Anglin O; Kambhampati AK; Milucky J; Chai SJ; Kirley PD; Alden NB; Armistead I; Meek J; Yousey-Hindes K; Anderson EJ; Openo KP; Teno K; Weigel A; Monroe ML; Ryan PA; Henderson J; Nunez VT; Bye E; Lynfield R; Poblete M; Smelser C; Barney GR; Spina NL; Bennett NM; Popham K; Billing LM; Shiltz E; Abdullah N; Sutton M; Schaffner W; Talbot HK; Ortega J; Price A; Garg S; Havers FP; MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(43):1513-1519. PubMed ID: 34710076 [TBL] [Abstract][Full Text] [Related]
18. [COVID-19: epidemiology and mutations : An update]. Hemmer CJ; Löbermann M; Reisinger EC Radiologe; 2021 Oct; 61(10):880-887. PubMed ID: 34542699 [TBL] [Abstract][Full Text] [Related]
19. CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant. Fumagalli MJ; Castro-Jorge LA; de Souza WM; de Azevedo PO; Hansen AW; Gazzinelli RT; da Fonseca BAL; Spilki FR; Figueiredo LTM Viruses; 2022 Feb; 14(2):. PubMed ID: 35215895 [TBL] [Abstract][Full Text] [Related]
20. Large-scale synchronized replacement of Alpha (B.1.1.7) variant by the Delta (B.1.617.2) variant of SARS-COV-2 in the COVID-19 pandemic. Liu Y; Feng A; Zhao S; Wang W; He D Math Biosci Eng; 2022 Feb; 19(4):3591-3596. PubMed ID: 35341265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]